Who are Aliskiren Hydrochlorothiazide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aliskiren/HCTZ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aliskiren-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aliskiren Hydrochlorothiazide — Competitive Intelligence Brief

Aliskiren Hydrochlorothiazide (Aliskiren Hydrochlorothiazide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct renin inhibitor / thiazide diuretic combination. Area: Cardiovascular.

marketed Direct renin inhibitor / thiazide diuretic combination Renin; sodium-chloride cotransporter (NCCT) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aliskiren Hydrochlorothiazide (Aliskiren Hydrochlorothiazide) — Novartis. Aliskiren hydrochlorothiazide combines a direct renin inhibitor with a thiazide diuretic to lower blood pressure through dual mechanisms of renin-angiotensin system suppression and sodium/fluid reduction.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aliskiren Hydrochlorothiazide TARGET	Aliskiren Hydrochlorothiazide	Novartis	marketed	Direct renin inhibitor / thiazide diuretic combination	Renin; sodium-chloride cotransporter (NCCT)
Aliskiren/HCTZ	Aliskiren/HCTZ	Novartis	phase 3	Direct renin inhibitor / thiazide diuretic combination	Renin; sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct renin inhibitor / thiazide diuretic combination class)

Novartis · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aliskiren Hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/aliskiren-hydrochlorothiazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab